Sichuan Kelun Botai

Kelun-Biotech is a leading clinical-stage biopharmaceutical company based in China, specializing in the development of innovative biologics, particularly antibody-drug conjugates (ADCs). The company has established a robust pipeline targeting high-prevalence cancers, supported by its proprietary OptiADC platform which optimizes linker and payload technologies. Kelun-Biotech gained significant international recognition through a multi-program strategic collaboration with Merck & Co. (MSD), representing one of the largest ADC licensing deals in history. Its lead candidate, sacituzumab tirumotecan (SKB264), is currently under regulatory review for triple-negative breast cancer. The company also develops monoclonal antibodies and bispecifics, aiming to address unmet medical needs in oncology and immunology.